Skip to content

Author

P. Sánchez-Juan

We have 4 of 298 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Sep 2026

Post mortem MRI of cholinergic white matter pathways across neurodegenerative diseases

Cholinergic white matter pathway degeneration is central in Alzheimer's disease and Lewy body disease and can be assessed in vivo using magnetic resonance imaging proxies, but neuropathological validation is limited.

F. López-González, M. Němý, C. Jerele et al. · 0 citations
Jul 2026

[18F]FDG PET outperforms MRI for detecting early tau-related neurodegeneration.

Hypometabolism is a sensitive and early marker of AD-related neurodegeneration, preceding MRI-detectable GM atrophy and more closely reflecting underlying tau pathology across disease stages.

Orfeas Vourkas, Linda Zhang, Andrés Jiménez-Pérez et al. · 0 citations
Open access Aug 2026

Alzheimer’s disease polygenic risk score associates with hippocampal subfield atrophy and immune-related genetic mechanism

Specific AD-SNPs enriched in immune-brain axis pathways rather than Aβ related processes, were associated with reduced volumes of CA1 and subiculum prior to dementia onset, which supports that AD-PRS may capture genetic susceptibility to concomitant neurodegenerative diseases frequently misdiagnosed as AD.

C. Olivé, I. de Rojas, Linda Zhang et al. · 0 citations
Open access Aug 2026

Exome analysis of 22,319 individuals links extremely rare copy-number variants and 22q11.21 dosage to Alzheimer risk.

It is concluded that rare coding CNVs in a proportion of AD-associated genes and 22q11.21 duplication as a strong AD-risk-decreasing factor increase AD risk and Conversely, 22q11.21 duplication as a strong AD-risk-decreasing factor is identified.

O. Quenez, Catherine Schramm, K. Cassinari et al. · 1 citation

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.